Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)

Summary

This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia.

The accuracy of these biomarkers as diagnostic criteria for prodromal dementia and MCI due to Alzheimer’s Disease appears to have low diagnostic benefit and / or clinical utility. The authors conclude that measuring protein in cerebrospinal fluid (CSF amyloid beta (Aβ40) or CSF Aβ42), as a single test, lacks the accuracy to identify patients with MCI who are likely to develop Alzheimer’s Disease or other forms of dementia.

Full Text Link

Reference

Ritchie, C. Smailagic, N. Noel-Storr, AH. [et al] (2014). Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Systematic Reviews. June 10th 2014; Issue 6: No. CD008782.

Advertisements

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.